The High Stakes of Sterile Manufacturing
A sterile injectable drug product that is contaminated with microorganisms or particulates can cause a patient serious harm or death. There is no sterilisation step at the end of aseptic fill-finish manufacturing: the product must be sterile when it is filled and sealed, and it must remain sterile throughout its shelf life. The entire manufacturing environment, the equipment, the personnel, the components, and the processes, must be designed and controlled to ensure that contamination cannot occur.
This is why aseptic fill-finish manufacturing is subject to the most stringent GMP requirements in pharmaceutical production, and why regulators inspect sterile facilities with particular attention to environmental monitoring data, process simulation (media fill) results, and the robustness of contamination control strategies.
The Aseptic Fill-Finish Process
Preparation of Components
Before any filling begins, the containers (vials, ampoules, or syringes), closures, and equipment must be prepared to the appropriate cleanliness standard. Glass vials are washed, depyrogenated in a hot air tunnel at temperatures sufficient to achieve a greater than 3-log reduction in endotoxin (typically above 250 degrees Celsius), and transferred to the filling suite under controlled conditions. Rubber stoppers and aluminium caps are washed, siliconised where required, and sterilised before use.
Sterile Filtration
For most liquid injectable products, the drug solution is sterilised by filtration through a 0.22 micrometre membrane filter immediately prior to filling. The filter must be integrity-tested before and after use to confirm that the membrane was intact throughout the filtration. For products that cannot be filtered (large molecules, suspensions, or products where the API is retained by the filter membrane), terminal sterilisation or alternative approaches must be considered.
Filling and Stoppering
The sterile drug solution is filled into containers under Grade A (ISO 5) conditions, typically within a RABS (Restricted Access Barrier System) or an isolator. Filling accuracy is controlled to defined weight or volume limits, and 100% in-process weight checks are standard for high-value products. Stoppering is performed within the same controlled environment immediately after filling to minimise the window of exposure.
Lyophilisation (Freeze-Drying)
For products that are unstable in solution, the filled vials are transferred to a freeze-dryer where the product is frozen and then dried under vacuum by sublimation. Lyophilisation improves long-term stability for biologics, vaccines, and chemically labile small molecules, at the cost of significantly longer cycle times and more complex manufacturing equipment. The lyophilisation cycle parameters including freezing rate, shelf temperature profile, and chamber pressure are critical process parameters that must be validated to ensure consistent product quality.
Sources of Contamination Risk
| Contamination Source | Mitigation Strategy | GMP Control |
| Personnel | Primary source of viable contamination; skin, hair, and respiration generate particles and microorganisms | Gowning qualification; training; grade A exclusion of personnel where possible via RABS or isolator |
| Environment | Airborne viable and non-viable particles from surrounding classified areas | Environmental monitoring (viable and non-viable); pressure differentials; HVAC validation |
| Equipment surfaces | Biofilm formation; carryover from previous products or cleaning agents | Validated cleaning and sterilisation procedures; residue limits |
| Raw materials and components | Non-sterile or endotoxin-contaminated containers or closures | Supplier qualification; incoming testing; depyrogenation validation |
| Drug solution | Microbial contamination during preparation or transfer | Bioburden monitoring prior to filtration; filter integrity; time limits on open vessel operations |
Process Simulation: The Media Fill
A process simulation, commonly called a media fill or aseptic process simulation, is the primary tool for demonstrating that the aseptic fill-finish process is capable of producing sterile product. The process is run using a microbiological growth medium instead of drug solution, and the filled containers are incubated to detect any growth indicative of contamination. EU GMP Annex 1, the comprehensive EU guidance on the manufacture of sterile medicinal products, requires media fills to be performed at a defined frequency, with acceptance criteria of zero growth in all units filled when the batch size is below 5,000 units, and a contamination rate not exceeding 0.1% for larger batches.
A failed media fill is a significant quality event that triggers a full investigation, a review of all product manufactured since the last successful simulation, and corrective actions before manufacturing can resume. The consequences make prevention, through robust facility design, well-trained personnel, and validated processes, far preferable to remediation.
Ardena’s Aseptic Fill-Finish Capabilities at Ghent
Ardena’s sterile manufacturing facility in Ghent provides aseptic fill-finish services for injectable drug products including vials, ampoules, and lyophilised products. The facility operates RABS for vial filling under Grade A conditions within a Grade B background, with lyophilisation capacity for products requiring freeze-drying. Environmental monitoring programmes and media fill qualification are maintained to EU GMP Annex 1 standards, and the facility is subject to regulatory inspection by the Belgian competent authority.
